AR093123A1 - Inhibidores de la tirosina-quinasa de bruton - Google Patents

Inhibidores de la tirosina-quinasa de bruton

Info

Publication number
AR093123A1
AR093123A1 ARP130103863A ARP130103863A AR093123A1 AR 093123 A1 AR093123 A1 AR 093123A1 AR P130103863 A ARP130103863 A AR P130103863A AR P130103863 A ARP130103863 A AR P130103863A AR 093123 A1 AR093123 A1 AR 093123A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
heterocycloalkyl
compounds
ch2nhr1
ch2nhc
Prior art date
Application number
ARP130103863A
Other languages
English (en)
Inventor
Dominique Romyr
Bhagirath Niala
Kennedy-Smith Joshua
Javier Lopez-Tapia Francisco
Mertz Eric
Qiao Qi
So Sung-Sau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR093123A1 publication Critical patent/AR093123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Los compuestos aquí descritos son útiles para modular la actividad de la Btk y para tratar enfermedades asociadas con una actividad excesiva de la Btk. Los compuestos son útiles además para tratar enfermedades inflamatorias y autoinmunes asociadas con la proliferación aberrante de células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen los compuestos de la fórmula (1) y por lo menos un vehículo, diluyente o excipiente. Reivindicación 1: Un compuesto de la fórmula (1) en la que: A es fenilo o piperidinilo; cada R¹ es con independencia halógeno, alquilo inferior, CH₂NHC(=O)R¹, CH₂N(CH₃)C(=O)R¹, CH₂NHC(=O)CH₂NHR¹, CH₂R¹ o CH₂NHR¹; n es el número 0, 1 ó 2; R¹ es fenilo, heteroarilo insaturado o parcialmente insaturado, bicíclico o monocíclico, o heterocicloalquilo opcionalmente sustituido por uno o más R¹; cada R¹ es con independencia alquilo inferior, halógeno, cicloalquilo, heterocicloalquilo, (alquilo inferior)-heterocicloalquilo, oxo, ciano-alquilo inferior, hidroxil-alquilo inferior o alcoxi inferior; R² es H, R³ o R⁴; R³ es C(=O)OR³, C(=O)R³ o C(=O)NH(CH₂)₂R³; R³ es H, alquilo inferior, heterocicloalquilo, amino u OH; R⁴ es alquilo inferior o heteroarilo opcionalmente sustituido por uno o más R⁴; y R⁴ es metilo, hidroxilo, amino, CH₂-CH₂N(CH₃)₂, OC(=O)CH₂CH₃, CH₂C(=O)OH, CH₂CH₂OH o C(=O)OH; o una sal farmacéuticamente aceptable del mismo.
ARP130103863A 2012-10-26 2013-10-24 Inhibidores de la tirosina-quinasa de bruton AR093123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718746P 2012-10-26 2012-10-26
US201361831443P 2013-06-05 2013-06-05

Publications (1)

Publication Number Publication Date
AR093123A1 true AR093123A1 (es) 2015-05-20

Family

ID=49488574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103863A AR093123A1 (es) 2012-10-26 2013-10-24 Inhibidores de la tirosina-quinasa de bruton

Country Status (12)

Country Link
US (1) US20150284394A1 (es)
JP (1) JP6139690B2 (es)
KR (1) KR20150060839A (es)
CN (1) CN104662024B (es)
AR (1) AR093123A1 (es)
BR (1) BR112015007513A2 (es)
CA (1) CA2881070A1 (es)
HK (1) HK1210779A1 (es)
MX (1) MX2015002975A (es)
RU (1) RU2619465C2 (es)
TW (1) TW201422619A (es)
WO (1) WO2014064131A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3444251B1 (en) * 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
RU2742122C2 (ru) * 2014-10-06 2021-02-02 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов ткб и их применение
WO2016065222A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
AU2015335703B2 (en) 2014-10-24 2020-05-21 Bristol-Myers Squibb Company Carbazole derivatives
EP3866926A1 (en) 2018-10-15 2021-08-25 Biogen MA Inc. Crystalline polymorphs of bruton's tyrosine kinase inhibitors
WO2020234780A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
EP4051679A1 (en) * 2019-10-30 2022-09-07 Biogen MA Inc. Condensed pyridazine or pyrimidine as btk inhibitors
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN113735859A (zh) * 2021-08-12 2021-12-03 安徽医科大学 一种激酶抑制剂
CN113583007B (zh) * 2021-08-31 2022-06-10 山东大学 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用
WO2023086521A1 (en) * 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
MY162590A (en) * 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
JP5606734B2 (ja) * 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2016077A2 (en) * 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JP2010170080A (ja) * 2008-12-24 2010-08-05 Sanyo Electric Co Ltd レンズ装置、撮影装置
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
US9029359B2 (en) * 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors

Also Published As

Publication number Publication date
US20150284394A1 (en) 2015-10-08
RU2619465C2 (ru) 2017-05-16
MX2015002975A (es) 2015-06-22
JP6139690B2 (ja) 2017-05-31
JP2015535226A (ja) 2015-12-10
CA2881070A1 (en) 2014-05-01
CN104662024B (zh) 2016-12-07
BR112015007513A2 (pt) 2017-07-04
TW201422619A (zh) 2014-06-16
HK1210779A1 (en) 2016-05-06
CN104662024A (zh) 2015-05-27
WO2014064131A3 (en) 2014-10-16
KR20150060839A (ko) 2015-06-03
RU2015117949A (ru) 2016-12-20
WO2014064131A2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
AR093123A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR093478A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR089682A1 (es) Compuestos de piridazina-amida
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR104362A1 (es) Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios
AR093128A1 (es) Inhibidores de la syk
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR081203A1 (es) Pirrolopirazinas como inhibidores de quinasas
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR087543A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR089527A1 (es) Inhibidores de bromodominios
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR088801A1 (es) Compuestos inhibidores de la fosfodiesterasa del tipo 10a
AR091976A1 (es) Inhibidores de proteasa ns3 de vhc
AR093832A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR092536A1 (es) Inhibidores de la tirosina-quinasa de bruton
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
AR107293A1 (es) COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias

Legal Events

Date Code Title Description
FB Suspension of granting procedure